Page 213 - Haematologica May 2022

Case Reports
Pre-published: December 30, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: AG, FL, YG, TEW developed the concept; TEW col- lected data on medical spontaneous HIT syndrome; MH and TR per- formed the immuno-electrophoresis; YG and JR developed and provid- ed the 1E12 monoclonal antibody and its deglycosylated form AG, TT, LS performed the laboratory studies; FL took care for the patient; AG, FL, TEW and YG wrote the manuscript; AG and FL verified the underlying data. All authors critically revised and approved the final version of the manuscript.
Funding: the study has been supported by Deutsche Forschungsgemeinschaft, grant/award numbers: 374031971-TRR 240 and KFO306.
References
1.Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee
replacement, infection, and parallels with vaccine-induced immune
thrombotic thrombocytopenia. Thromb Res. 2021;204:40-51. 2.Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-
19 vaccination. N Engl J Med. 2021;384(22):2092-2101.
3. Vayne C, Nguyen TH, Rollin J, et al. Characterization of new mon- oclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb
Haemost. 2021;121(3):322-331.
4. Greinacher A, Selleng K, Mayerle J, et al. Anti-platelet factor 4 anti-
bodies causing VITT do not cross-react with SARS-CoV-2 spike pro-
tein. Blood. 2021;138(14):1269-1277.
5. Faille D, Hurtado-Nedelec M, Ouedrani A, et al. Isolation of a mon-
oclonal IgG kappa with functional autoantibody activity against platelet factor 4/heparin from a patient with a monoclonal gam- mopathy of undetermined significance and clinically overt heparin thrombocytopenia. Res Pract Thromb Haemost. 2017;1(Suppl 1):S1355.
haematologica | 2022; 107(5)
1221